https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-wor-worthington-organic-growth-rebounds-after-a-slow-close The Tip Desk en 2026-09-23 Worthington Organic Growth Rebounds After a Slow Close https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-tho-thor-withholds-fiscal-2027-guidance-after-profit-collapse The Tip Desk en 2026-09-23 Thor Withholds Fiscal 2027 Guidance After Profit Collapse https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-kbh-kb-home-backlog-rises-after-four-year-stagnation The Tip Desk en 2026-09-23 KB Home Backlog Rises After Four-Year Stagnation https://tip.inventingindices.com/marketbrain-2026-09-23-earnings-azo-autozone-reverses-gross-margin-decline-on-tariff-refunds The Tip Desk en 2026-09-23 AutoZone Reverses Gross-Margin Decline on Tariff Refunds https://tip.inventingindices.com/marketbrain-2026-09-23-deals-talo-talos-energy-closes-420-million-gulf-of-america-asset-purcha The Tip Desk en 2026-09-23 Talos Energy Closes $420 Million Gulf of America Asset Purchase https://tip.inventingindices.com/marketbrain-2026-09-23-deals-prgs-progress-software-to-buy-domo-platform-in-400-million-cash-d The Tip Desk en 2026-09-23 Progress Software to Buy Domo Platform in $400 Million Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-23-deals-lgnd-ligand-to-buy-santen-s-ryjunea-for-23-million The Tip Desk en 2026-09-23 Ligand to Buy Santen's Ryjunea for $23 Million https://tip.inventingindices.com/marketbrain-2026-09-23-deals-cgnx-cognex-to-buy-realsense-in-500-million-cash-deal The Tip Desk en 2026-09-23 Cognex to Buy RealSense in $500 Million Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-vk2735-overview The Tip Desk en 2026-09-23 VK2735: a smaller developer is testing several treatment patterns https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-vk2735-maintenance-update The Tip Desk en 2026-09-23 VK2735: a maintenance study asks how much treatment can be spaced out https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-upadacitinib-overview The Tip Desk en 2026-09-23 Upadacitinib: an oral approved option with a specific treatment setting https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-ulcerative-colitis-comparison The Tip Desk en 2026-09-23 Ulcerative colitis: compare the treatment setting before comparing remission https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tulisokibart-overview The Tip Desk en 2026-09-23 Tulisokibart: a TL1A program moves from acquisition to Phase 3 evidence https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tirzepatide-overview The Tip Desk en 2026-09-23 Tirzepatide: an approved dual agonist as a reference point https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-semaglutide-overview The Tip Desk en 2026-09-23 Semaglutide: the established benchmark keeps developing https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-risankizumab-overview The Tip Desk en 2026-09-23 Risankizumab: an approved IL-23 comparator with a long follow-up record https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-retatrutide-overview The Tip Desk en 2026-09-23 Retatrutide: Phase 3 results do not yet equal an approval https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-overview The Tip Desk en 2026-09-23 Petrelintide: amylin development now has a major partner https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-enicepatide-introduction The Tip Desk en 2026-09-23 Petrelintide and enicepatide enter a separate combination study https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-orforglipron-overview The Tip Desk en 2026-09-23 Orforglipron: oral treatment has crossed the approval boundary https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-obesity-comparison The Tip Desk en 2026-09-23 Obesity development: mechanisms and treatment patterns, not a league table https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-obefazimod-overview The Tip Desk en 2026-09-23 Obefazimod: the clinical story now meets the filing and funding story https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-obefazimod-financing-update The Tip Desk en 2026-09-23 Obefazimod: financing context changes while a filing remains planned https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-mirikizumab-overview The Tip Desk en 2026-09-23 Mirikizumab: induction and maintenance form one approval story https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-maridebart-cafraglutide-overview The Tip Desk en 2026-09-23 MariTide: dosing frequency is part of the development question https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-etrasimod-overview The Tip Desk en 2026-09-23 Etrasimod: the ownership history and trial design both matter https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-enicepatide-overview The Tip Desk en 2026-09-23 Enicepatide: a renamed program enters a broader obesity portfolio https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-enicepatide-diabetes-update The Tip Desk en 2026-09-23 Enicepatide: diabetes-population evidence adds a new chapter https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-duvakitug-overview The Tip Desk en 2026-09-23 Duvakitug: shared funding accompanies a separate TL1A development path https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-danuglipron-overview The Tip Desk en 2026-09-23 Danuglipron: a discontinued program remains part of the obesity story https://tip.inventingindices.com/marketbrain-2026-09-22-uk-earnings-kgf-kingfisher-upgrades-profit-guidance-as-screwfix-drives-growt The Tip Desk en 2026-09-22 Kingfisher upgrades profit guidance as Screwfix drives growth https://tip.inventingindices.com/marketbrain-2026-09-22-newsroom-2026-09 The Tip Desk en 2026-09-22 Microsoft Corporation (MSFT) expands datacenter training https://tip.inventingindices.com/marketbrain-2026-09-22-fathom-the-uneven-conversion-of-earnings-into-cash The Tip Desk en 2026-09-22 The Uneven Conversion of Earnings Into Cash https://tip.inventingindices.com/marketbrain-2026-09-22-earnings-anab-anaptysbio-records-177-million-tax-driven-profit The Tip Desk en 2026-09-22 AnaptysBio Records $177 Million Tax-Driven Profit https://tip.inventingindices.com/marketbrain-2026-09-22-deals-wwd-woodward-to-move-santa-clarita-aerospace-production-to-spart The Tip Desk en 2026-09-22 Woodward to Move Santa Clarita Aerospace Production to Spartanburg https://tip.inventingindices.com/marketbrain-2026-09-22-deals-road-construction-partners-adds-roads-inc-of-nwf The Tip Desk en 2026-09-22 Construction Partners Adds Roads, Inc. of NWF https://tip.inventingindices.com/marketbrain-2026-09-22-deals-ptct-ptc-completes-st-920-fabry-gene-therapy-purchase The Tip Desk en 2026-09-22 PTC Completes ST-920 Fabry Gene Therapy Purchase https://tip.inventingindices.com/marketbrain-2026-09-22-deals-prth-investor-group-to-take-priority-technology-private-in-1-6-bi The Tip Desk en 2026-09-22 Investor Group to Take Priority Technology Private in $1.6 Billion Cash Deal https://tip.inventingindices.com/marketbrain-2026-09-22-deals-ele-elemental-royalty-to-buy-orion-in-290-million-mixed-deal The Tip Desk en 2026-09-22 Elemental Royalty to Buy Orion in $290 Million Mixed Deal https://tip.inventingindices.com/marketbrain-2026-09-22-deals-dks-dick-s-completes-2-5-billion-foot-locker-acquisition The Tip Desk en 2026-09-22 DICK’S Completes $2.5 Billion Foot Locker Acquisition